Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer

Jun 2, 2022

Article Link: https://www.businesswire.com/news/home/20220602005856/en/Resilience-and-MD-Anderson-Launch-Joint-Venture-to-Accelerate-Development-and-Manufacturing-of-Innovative-Cell-Therapies-for-Cancer

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 7, 2026

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

May 5, 2026

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...

Apr 17, 2026

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...

Back